2023 World Conference on Lung Cancer (Posters)-EP12.01. Durable Response to High-Dose Aumolertinib 165mg After Local Progression in EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases

EP12.01. Durable Response to High-Dose Aumolertinib 165mg After Local Progression in EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases - PDF(Abstract)

Back to course

Pdf Summary

A case report presented at the WCLC 2023 conference discusses the use of high-dose aumolertinib in a patient with metastatic non-small cell lung cancer (NSCLC) and brain metastases. The patient, a 46-year-old female, initially received standard dose aumolertinib (110mg daily) after confirmation of an EGFR exon 19 deletion mutation. The treatment resulted in excellent overall response, with partial response in lung lesions and complete response in brain metastases. However, after 17 months, the patient experienced local progression in the lung lesion while the brain lesions continued to respond well. To better control the local progression, the dose of aumolertinib was increased to 165mg, which the patient tolerated well. Recent imaging studies showed no evidence of recurrent brain metastases and stable disease in the chest. The patient has demonstrated a durable response of over 33 months to aumolertinib with minimal adverse events. <br /><br />NSCLC patients with brain metastases have a poor prognosis, particularly those with EGFR mutations. Aumolertinib, a third-generation EGFR-TKI, has better penetration into the central nervous system and has shown promising results in clinical trials. Continuing TKI therapy has been recommended in NSCLC guidelines when patients locally progress after initial EGFR-TKI treatment. In this case, the patient's response to high-dose aumolertinib suggests that it can be well tolerated with prolonged efficacy in EGFR-mutated NSCLC patients with brain metastases after local progression with a standard dose. <br /><br />This case report highlights the potential of high-dose aumolertinib as an optional strategy for NSCLC patients who cannot tolerate other local treatments such as radiation therapy. The findings suggest that high-dose aumolertinib may provide a durable response and minimal adverse events in these patients.

Asset Subtitle

Qingqing Zhu

Meta Tag

Speaker Qingqing Zhu

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

case report

WCLC 2023 conference

high-dose aumolertinib

metastatic non-small cell lung cancer

NSCLC

brain metastases

EGFR exon 19 deletion mutation

partial response

complete response

local progression